Asset Details
Do you wish to reserve the book?
The Combination of Carmustine Wafers and Fotemustine in Recurrent Glioblastoma Patients : A Monoinstitutional Experience
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Combination of Carmustine Wafers and Fotemustine in Recurrent Glioblastoma Patients : A Monoinstitutional Experience
Do you wish to request the book?
The Combination of Carmustine Wafers and Fotemustine in Recurrent Glioblastoma Patients : A Monoinstitutional Experience
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The Combination of Carmustine Wafers and Fotemustine in Recurrent Glioblastoma Patients : A Monoinstitutional Experience
2014
Overview
Background. To date, there is no standard treatment for recurrent glioblastoma. We analyzed the feasibility of second surgery plus carmustine wafers followed by intravenous fotemustine. Methods. Retrospectively, we analyzed patients with recurrent glioblastoma treated with this multimodal strategy. Results. Twenty-four patients were analyzed. The median age was 53.6; all patients had KPS between 90 and 100; 19 patients (79%) performed a gross total resection > 98% and 5 (21%) a gross total resection > 90%. The median progression-free survival from second surgery was 6 months (95% CI 3.9–8.05) and the median OS was 14 months (95% CI 11.1–16.8 months). Toxicity was predominantly haematological: 5 patients (21%) experienced grade 3-4 thrombocytopenia and 3 patients (12%) grade 3-4 leukopenia. Conclusion. This multimodal strategy may be feasible in patients with recurrent glioblastoma, in particular, for patients in good clinical conditions.
Publisher
Hindawi Puplishing Corporation,Hindawi Publishing Corporation,John Wiley & Sons, Inc
Subject
/ Aged
/ Antineoplastic Combined Chemotherapy Protocols - adverse effects
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Brain Neoplasms - drug therapy
/ Carmustine - adverse effects
/ Carmustine - therapeutic use
/ Female
/ Humans
/ Karnofsky Performance Status
/ Male
/ Nitrosourea Compounds - adverse effects
/ Nitrosourea Compounds - therapeutic use
/ Oncology
/ Organophosphorus Compounds - adverse effects
/ Organophosphorus Compounds - therapeutic use
/ Surgery
/ Toxicity
/ Tumors
